Activity landscape of DNA methyltransferase inhibitors bridges chemoinformatics with epigenetic drug discovery

被引:18
|
作者
Jesus Naveja, J. [1 ,2 ]
Medina-Franco, Jose L. [1 ]
机构
[1] Univ Nacl Autonoma Mexico, Dept Farm, Fac Quim, Mexico City 04510, DF, Mexico
[2] Univ Nacl Autonoma Mexico, PECEM, Fac Med, Mexico City 04510, DF, Mexico
关键词
activity cliffs; cancer; data mining; DNA methyltransferase; epi-informatics; structure-activity relationships; CONSENSUS-ACTIVITY-CLIFFS; CANCER; METHYLATION; SIMILARITY; TARGETS; PREDICTION; DOCKING; MAPS;
D O I
10.1517/17460441.2015.1073257
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Activity landscapes are valuable tools for exploring systematically the structure-activity relationships (SAR) of chemical databases. Their application to analyze the SAR of DNA methyltransferase (DNMT) inhibitors, which are attractive compounds as potential epi-drugs or epi-probes, provides useful information to identify pharmacophoric regions and plan the development of predictive models and virtual screening. Areas covered: This paper highlights different approaches for conducting SAR analysis of datasets with a particular focus on the activity landscape methodology. SAR information of DNMT inhibitors (DNMTi), stored in a public database, is surveyed to further illustrate concepts and generalities of activity landscape modeling with a special emphasis on structure-activity similarity (SAS) maps. Expert opinion: The increasing SAR information reported for DNMTi opens up avenues to implement activity landscape methods. Despite several activity landscape methods, such as SAS maps, being well established, these need further refinement. For instance, novel combinations of multiple representations, such as the addition of Z-values of similarity (fusion-Z), lead to more robust representations of consensus SAS maps. Density SAS maps improve the visualization of the SAR. A survey of activity cliffs (i.e., pairs of compounds with high structural similarity but high differences in potency) of DNMTi available in a public database suggest that it is feasible to develop predictive models for non-nucleoside DNMTi using approaches such as quantitative structure-activity relationships and that non-nucleoside DNMTi in ChEMBL can be used as query molecules in similarity-based virtual screening.
引用
收藏
页码:1059 / 1070
页数:12
相关论文
共 50 条
  • [1] Exploring the epigenetic drug discovery landscape
    Prachayasittikul, Veda
    Prathipati, Philip
    Pratiwi, Reny
    Phanus-umporn, Chuleeporn
    Malik, Aijaz Ahmad
    Schaduangrat, Nalini
    Seenprachawong, Kanokwan
    Wongchitrat, Prapimpun
    Supokawej, Aungkura
    Prachayasittikul, Virapong
    Wikberg, Jarl E. S.
    Nantasenamat, Chanin
    EXPERT OPINION ON DRUG DISCOVERY, 2017, 12 (04) : 345 - 362
  • [2] Epigenetic cancer therapies: DNA methyltransferase inhibitors
    Strathdee, G
    Brown, R
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (06) : 747 - 754
  • [3] Computational Methods for Epigenetic Drug Discovery: A Focus on Activity Landscape Modeling
    Jesus Naveja, J.
    Iluhi Oviedo-Osornio, C.
    Medina-Franco, Jose L.
    COMPUTATIONAL MOLECULAR MODELLING IN STRUCTURAL BIOLOGY, 2018, 113 : 65 - 83
  • [4] DNA methyltransferase inhibitors and the development of epigenetic cancer therapies
    Lyko, F
    Brown, R
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (20): : 1498 - 1506
  • [5] Angiostatic activity of DNA methyltransferase inhibitors
    Hellebrekers, DMEI
    Jair, KW
    Viré, E
    Eguchi, S
    Hoebers, NTH
    Fraga, MF
    Esteller, M
    Fuks, F
    Baylin, SB
    van Engeland, M
    Griffioen, AW
    MOLECULAR CANCER THERAPEUTICS, 2006, 5 (02) : 467 - 475
  • [6] A Computational Approach for the Discovery of Novel DNA Methyltransferase Inhibitors
    Kritsi, Eftichia
    Christodoulou, Paris
    Tsiaka, Thalia
    Georgiadis, Panagiotis
    Zervou, Maria
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2024, 46 (04) : 3394 - 3407
  • [7] DNA Methyltransferase Inhibitors and Their Emerging Role in Epigenetic Therapy of Cancer
    Gnyszka, Agnieszka
    Jastrzebski, Zenon
    Flis, Sylwia
    ANTICANCER RESEARCH, 2013, 33 (08) : 2989 - 2996
  • [8] DNA Methyltransferase-1 Inhibitors as Epigenetic Therapy for Cancer
    Singh, Varinder
    Sharma, Prince
    Capalash, Neena
    CURRENT CANCER DRUG TARGETS, 2013, 13 (04) : 379 - 399
  • [9] Epigenetic Drug Discovery: Targeting DNA Methyltransferases
    Foulks, Jason M.
    Parnell, K. Mark
    Nix, Rebecca N.
    Chau, Suzanna
    Swierczek, Krzysztof
    Saunders, Michael
    Wright, Kevin
    Hendrickson, Thomas F.
    Ho, Koc-Kan
    McCullar, Michael V.
    Kanner, Steven B.
    JOURNAL OF BIOMOLECULAR SCREENING, 2012, 17 (01) : 2 - 17
  • [10] Discovery and development of DNA methyltransferase inhibitors using in silico approaches
    Medina-Franco, Jose L.
    Mendez-Lucio, Oscar
    Duenas-Gonzalez, Alfonso
    Yoo, Jakyung
    DRUG DISCOVERY TODAY, 2015, 20 (05) : 569 - 577